Fabio Del Bello1, Farhana Sakloth1, John S Partilla2, Michael H Baumann2, Richard A Glennon3. 1. Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box 980540, Richmond, VA 23298, USA. 2. Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. 3. Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Box 980540, Richmond, VA 23298, USA. Electronic address: glennon@vcu.edu.
Abstract
N-Methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA; 'Ecstasy'; 1) and its β-keto analog methylone (MDMC; 2) are popular drugs of abuse. Little is known about their ring-expanded ethylenedioxy homologs. Here, we prepared N-methyl-(3,4-ethylenedioxyphenyl)-2-aminopropane (EDMA; 3), both of its optical isomers, and β-keto EDMA (i.e., EDMC; 4) to examine their effects at transporters for serotonin (SERT), dopamine (DAT), and norepinephrine (NET). In general, ring-expansion of the methylenedioxy group led to a several-fold reduction in potency at all three transporters. With respect to EDMA (3), S(+)3 was 6-fold, 50-fold, and 8-fold more potent than its R(-) enantiomer at SERT, DAT, and NET, respectively. Overall, in the absence of a β-carbonyl group, the ethylenedioxy (i.e., 1,4-dioxane) substituent seems better accommodated at SERT than at DAT and NET.
N-Methyl-(3,4-methylenedioxyphenyl)-2-aminopropane (n class="Chemical">MDMA; 'Ecstasy'; 1) and its β-keto analog methylone (MDMC; 2) are popular drugs of abuse. Little is known about their ring-expanded ethylenedioxy homologs. Here, we prepared N-methyl-(3,4-ethylenedioxyphenyl)-2-aminopropane (EDMA; 3), both of its optical isomers, and β-keto EDMA (i.e., EDMC; 4) to examine their effects at transporters for serotonin (SERT), dopamine (DAT), and norepinephrine (NET). In general, ring-expansion of the methylenedioxy group led to a several-fold reduction in potency at all three transporters. With respect to EDMA (3), S(+)3 was 6-fold, 50-fold, and 8-fold more potent than its R(-) enantiomer at SERT, DAT, and NET, respectively. Overall, in the absence of a β-carbonyl group, the ethylenedioxy (i.e., 1,4-dioxane) substituent seems better accommodated at SERT than at DAT and NET.
Authors: F Sakloth; R Kolanos; P D Mosier; J S Bonano; M L Banks; J S Partilla; M H Baumann; S S Negus; R A Glennon Journal: Br J Pharmacol Date: 2015-02-27 Impact factor: 8.739
Authors: Amy J Eshleman; Katherine M Wolfrum; Meagan G Hatfield; Robert A Johnson; Kevin V Murphy; Aaron Janowsky Journal: Biochem Pharmacol Date: 2013-04-10 Impact factor: 5.858
Authors: L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Vincent Setola; Sandra J Hufeisen; K Jane Grande-Allen; Ivan Vesely; Richard A Glennon; Bruce Blough; Richard B Rothman; Bryan L Roth Journal: Mol Pharmacol Date: 2003-06 Impact factor: 4.436
Authors: Dino Luethi; Karolina E Kolaczynska; Melanie Walter; Masaki Suzuki; Kenner C Rice; Bruce E Blough; Marius C Hoener; Michael H Baumann; Matthias E Liechti Journal: J Psychopharmacol Date: 2019-04-30 Impact factor: 4.153
Authors: Bruce E Blough; Ann M Decker; Antonio Landavazo; Ojas A Namjoshi; John S Partilla; Michael H Baumann; Richard B Rothman Journal: Psychopharmacology (Berl) Date: 2018-10-20 Impact factor: 4.530